EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Narlumosbart: First Approval

Sohita Dhillon

Drugs · 2024

DOI: 10.1007/s40265-023-01985-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drugs, 2024. Verfasst von Sohita Dhillon. Beteiligte Einrichtung: Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com. Hauptthemen laut MEDLINE: Bone Resorption, Bone Neoplasms, Giant Cell Tumor of Bone, Bone Density Conservation Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Narlumosbart () is a recombinant, fully human, anti-receptor activator of nuclear factor kappa-Β ligand (RANKL) IgG4 monoclonal antibody being developed by CSPC Pharmaceutical and its wholly owned subsidiary Shanghai Jinmante Biotechnology for the treatment of giant cell tumour of bone (GCTB), bone metastases from solid tumours and osteoporosis. The RANK/RANKL signalling pathway plays a pivotal role in osteoclastogenesis and in the pathogenesis of GCTB. Narlumosbart specifically binds to RANKL and blocks the interaction of RANKL with RANK, thus inhibiting osteoclastogenesis and bone resorption by osteoclasts. In September 2023, narlumosbart received conditional first approval in China for the treatment of adults with GCTB that is unresectable or when surgical resection would result in severe functional disability. Clinical studies of narlumosbart for bone metastases, postmenopausal osteoporosis and glucocorticoid-induced osteoporosis are underway in China. This article summarizes the milestones in the development of narlumosbart leading to this first approval for the treatment of adults with GCTB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone ResorptionBone NeoplasmsGiant Cell Tumor of BoneBone Density Conservation AgentsOsteoporosisAdultFemaleHumansChinaOsteoclasts

Substanzen

Bone Density Conservation Agents

Autor:innen und Institutionen

  • Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Zitieren

APA

Dhillon, S. (2024). Narlumosbart: First Approval. Drugs. https://doi.org/10.1007/s40265-023-01985-3

Vancouver

Dhillon S. Narlumosbart: First Approval. Drugs. 2024. doi:10.1007/s40265-023-01985-3

BibTeX
@article{Dhillon2024,
  author = {Dhillon, Sohita},
  title = {Narlumosbart: First Approval},
  journal = {Drugs},
  year = {2024},
  doi = {10.1007/s40265-023-01985-3}
}
Kostenlos starten →